Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease (PRO-MH2)

Institut National de la Santé Et de la Recherche Médicale, France

Status: Completed

Conditions: Huntington Disease

Treatments: Other: 31-Phosphorus RMN Spectroscopy

Study type: Interventional

Funder types: Other

Identifiers

NCT01696708

2012-A01063-40 (Registry Identifier)

C12-49

Details and patient eligibility

About

The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• UHDRS < 50
• Age > 18 years
• Ability to undergo MR scanning
• Covered by french social security

Exclusion criteria

• Evidence of psychiatric disorder
• Attendant neurological disorder
• Contraindications to MRI (claustrophobia, metallic or material implants)
• Severe head injury
• Unable to understand the protocol
• Pregnancy
• Failure to give informed consent
• Subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent)
• Unwillingness to be informed in case of abnormal MRI

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

Patients

Other group

Description:

31-Phosphorus RMN Spectroscopy

Treatment:

Other: 31-Phosphorus RMN Spectroscopy

Volunteers

Other group

Description:

31-Phosphorus RMN Spectroscopy

Treatment:

Other: 31-Phosphorus RMN Spectroscopy